Contents
In recent weeks, PhRMA has amplified a new messaging campaign, including ads and videos such as
“End Middlemen Markups. Put American Patients First.”
These pieces argue that intermediaries in the drug supply chain are driving up costs and suggest that hospitals and safety-net providers may be contributing to the problem.
It’s a compelling narrative, simple, emotional, and easy to digest.
However, it overlooks crucial facts about how drug pricing operates, what drives patient costs, and the vital role of the 340B Drug Pricing Program in supporting vulnerable communities.
Understanding the Narrative Behind the Ads
The PhRMA videos focus heavily on “middlemen” as the core reason drug prices are high. While intermediaries like PBMs and insurers do contribute to system inefficiencies, the ads blur an important distinction:
Profit-seeking middlemen are not the same as safety-net providers.
The videos insinuate that providers who participate in 340B are part of the markup problem, ignoring that these hospitals and clinics reinvest savings directly back into patient care. This oversimplification leads to misperceptions about 340B and its purpose.
The Purpose of 340B, And Why It Still Matters
Created in 1992 with strong bipartisan support, the 340B Drug Pricing Program enables eligible hospitals and health centers to stretch scarce resources and deliver more care to low-income, uninsured, and rural patients.
340B savings commonly support:
- Free or discounted medications
- Oncology care access
- HIV and hepatitis C treatment programs
- Chronic disease management
- Behavioral health and substance-use services
- Rural outreach and telehealth expansion
- Transportation, housing assistance, and care-coordination services
Far from a profit engine, 340B is often the difference between whether vital services exist at all.
Evidence That Counters PhRMA’s Claims
Independent oversight agencies and national healthcare organizations consistently affirm the program’s value:
- GAO (2018) found that 340B hospitals provide more uncompensated care than non-340B hospitals.
- AHA (2023) reports that 340B supports a wide range of community programs and patient-assistance services.
- 340B Health (2024) documents billions in annual savings reinvested directly into care access and expanded clinical services.
- Ongoing rural hospital closures show that financial stability is fragile, and 340B is often the only margin supporting essential services.
If 340B were truly a profit-driven “middleman” loophole, rural hospitals would be flourishing.
Instead, many are closing, a sign that safety-net providers need 340B, not that they are benefiting excessively from it.
What the Ads Overlook: The Real Complexity Ahead
While the PhRMA messaging frames 340B simplistically, real-world operations are becoming increasingly complex. Covered entities must now navigate:
- The Inflation Reduction Act’s Maximum Fair Price (MFP) rules
- HRSA’s transition to retrospective 340B rebates
- Expanded manufacturer validation requirements
- Contract pharmacy restrictions
- Increased audit and reporting expectations
These changes demonstrate the opposite of what the ads suggest:
340B is becoming more regulated, more scrutinized, and more administratively burdensome, not a channel for unchecked margins.
The Bottom Line: Protecting Access, Not Profits
The PhRMA narrative tries to position hospitals and safety-net providers as part of the cost problem. But weakening 340B would not reduce drug prices, it would:
- Accelerate rural hospital closures
- Reduce access to primary and specialty care
- Eliminate patient-assistance and medication-access programs
- Increase disparities in underserved communities
When 340B is protected:
- Providers maintain essential services
- Patients gain access to affordable medications
- Communities retain stable care networks
340B is not the middleman problem; it is a patient-access solution.
Conclusion
PhRMA’s ads raise legitimate questions about drug supply-chain inefficiencies. But they miscast safety-net providers and ignore the indispensable role of 340B in supporting care for millions of vulnerable Americans.
In a healthcare system burdened by rising costs and persistent inequity, the 340B program continues to be one of the few tools that reliably delivers local, community-level benefits.
Preserving it isn’t just sound policy; it is essential for the patients and communities who depend on it every day.
References
- Health Resources and Services Administration (HRSA). 340B Drug Pricing Program Materials and Guidance.
- GAO Report GAO-18-480. Drug Discount Program: Federal Oversight of Compliance at 340B Contract Pharmacies Needs Improvement. June 2018.
- 340B Health. Community Impact Report. 2024.
- American Hospital Association (AHA). The 340B Program: A Critical Program for Hospitals and Patients. 2023.
- U.S. Department of Health & Human Services, ASPE. Drug Pricing Trends and Inflation Reduction Act Impacts. 2024.
